食品和药物管理局首先批准鼻涕喷雾(etripamil),用于在家中治疗PSVT患者的快速心跳。 FDA approves first nasal spray, etripamil, for home treatment of rapid heartbeats in PSVT patients.

FDA已批准依曲帕米（Cardamyst）鼻喷剂，这是首个针对成人急性阵发性室上性心动过速（PSVT）的自我给药治疗药物，使患者能够在家中控制快速心率发作。 The FDA has approved etripamil (Cardamyst) nasal spray, the first self-administered treatment for acute paroxysmal supraventricular tachycardia (PSVT) in adults, allowing patients to manage rapid heart rate episodes at home. 根据RAPID第3阶段的试验,64%使用 etripamil 的病人在30分钟内恢复了正常的心脏节奏,而安慰剂为31%,中间转换时间为17.2分钟。 Based on the phase 3 RAPID trial, 64% of patients using etripamil restored normal heart rhythm within 30 minutes, compared to 31% on placebo, with a median conversion time of 17.2 minutes. 该药物是钙渠道阻塞器,经精心制造,具有轻微的鼻部副作用,没有发生严重不良事件。 The drug, a calcium channel blocker, was well-tolerated, with mild nasal side effects and no serious adverse events. 预计到2026年初可在零售药店买到,并可能减少紧急探访,改善创伤后精神紧张症患者的生活质量。 It is expected to be available in retail pharmacies by early 2026 and may reduce emergency visits and improve quality of life for PSVT patients.